Doloteffin

01/01/2005 - "A 1-year follow-up after a pilot study with Doloteffin for low back pain."
04/01/2002 - "Thus, Doloteffin is well worth considering for osteoarthritic knee and hip pain and nonspecific low back pain."
01/01/2005 - "To complete a year's follow-up on patients from a 6-week double-blind pilot comparison between 44 Doloteffin patients and 44 rofecoxib patients being treated for acute exacerbations of chronic low back pain. "
01/01/2003 - "This randomized, double-dummy, double-blind pilot study of acutely exacerbated low back pain was aimed to inform a definitive comparison between Doloteffin, a proprietary extract of Harpagophytum, and rofecoxib, a selective inhibitor of cyclo-oxygenase-2 (COX-2). "
01/01/2003 - "A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain."

12/01/2003 - "In order to add data on the efficacy and long-term safety of an aqueous extract (Doloteffin; 2400 mg extract daily, corresponding to 50 mg harpagoside), which has been tested successfully in patients with low back pain, an uncontrolled multicentre drug surveillance study for about 12 weeks was conducted in 75 patients with arthrosis of the hip or knee. "

04/01/2002 - "Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip."
04/01/2002 - "Thus, Doloteffin is well worth considering for osteoarthritic knee and hip pain and nonspecific low back pain."
06/01/2007 - "We recruited 114 patients (56 with chronic nonspecific low back pain, 37 with osteoarthritic knee and 21 with osteoarthritic hip pain) into a surveillance of the effects of taking Doloteffin at a dose providing 60 mg harpagoside per day for up to 54 weeks. "